NZ629828A - Methods for the treatment of b cell-mediated inflammatory diseases - Google Patents

Methods for the treatment of b cell-mediated inflammatory diseases

Info

Publication number
NZ629828A
NZ629828A NZ629828A NZ62982813A NZ629828A NZ 629828 A NZ629828 A NZ 629828A NZ 629828 A NZ629828 A NZ 629828A NZ 62982813 A NZ62982813 A NZ 62982813A NZ 629828 A NZ629828 A NZ 629828A
Authority
NZ
New Zealand
Prior art keywords
cell
treatment
methods
inflammatory diseases
mediated inflammatory
Prior art date
Application number
NZ629828A
Other languages
English (en)
Inventor
Ernest S Smith
Maurice Zauderer
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of NZ629828A publication Critical patent/NZ629828A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ629828A 2012-03-02 2013-03-01 Methods for the treatment of b cell-mediated inflammatory diseases NZ629828A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606049P 2012-03-02 2012-03-02
PCT/US2013/028602 WO2013130959A1 (en) 2012-03-02 2013-03-01 Methods for the treatment of b cell-mediated inflammatory diseases

Publications (1)

Publication Number Publication Date
NZ629828A true NZ629828A (en) 2017-05-26

Family

ID=47844534

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ629828A NZ629828A (en) 2012-03-02 2013-03-01 Methods for the treatment of b cell-mediated inflammatory diseases

Country Status (10)

Country Link
US (1) US9890213B2 (enExample)
EP (1) EP2820045B1 (enExample)
JP (1) JP6193275B2 (enExample)
KR (1) KR102090969B1 (enExample)
CN (1) CN104520323B (enExample)
AU (1) AU2013225812B2 (enExample)
CA (1) CA2865928C (enExample)
IN (1) IN2014DN08199A (enExample)
NZ (1) NZ629828A (enExample)
WO (1) WO2013130959A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2427212T3 (enExample) 2009-05-08 2018-01-20
MX353476B (es) 2010-09-02 2018-01-15 Vaccinex Inc Star Anticuerpos anti-cxcl13 y metodos para usarlos.
ES2669209T3 (es) 2011-10-11 2018-05-24 Vaccinex, Inc. Uso de moléculas de unión a semaforina-4D para la modulación de la permeabilidad de la barrera hematoencefálica
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
KR102176962B1 (ko) 2013-01-31 2020-11-10 백시넥스 인코포레이티드 면역글로불린 a 수준을 증가시키기 위한 방법
CA3098741A1 (en) 2013-06-25 2014-12-31 Vaccinex, Inc. Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
AU2017252427B2 (en) 2016-04-22 2023-07-13 Vaccinex, Inc. Integral membrane protein display on poxvirus extracellular enveloped virions
MX2019001453A (es) 2016-08-02 2019-06-20 Vaccinex Inc Metodos mejorados para producir genotecas de polinucleotidos en virus vacuna/ celulas eucariotas.
CA3036509C (en) * 2016-09-19 2022-10-25 I-Mab Anti-gm-csf antibodies and uses thereof
EP3801558A4 (en) * 2018-05-31 2022-03-09 Glycom A/S HMOS BLEND FOR THE TREATMENT OF AUTOIMMUNE DISEASES
BR112021000583A2 (pt) * 2018-09-18 2021-04-06 I-Mab Biopharma Us Limited Anticorpo, composição, célula isolada, polinucleotídeo, métodos para supressão de uma resposta imune ou tratamento de uma doença ou distúrbio autoimune, para tratamento de câncer e para detecção da expressão de uma proteína, e, uso de um anticorpo.

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
EP0428534B1 (en) 1988-06-14 1995-03-29 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
EP0521985B1 (en) 1990-03-20 1997-09-24 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
DE69128253T2 (de) 1990-10-29 1998-06-18 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
EP0574395B1 (en) 1990-11-09 2002-06-12 GILLIES, Stephen D. Cytokine immunoconjugates
AP257A (en) 1991-04-26 1993-06-03 Surface Active Ltd A method of releasing an antigen from an antibody and methods for their use in diagnosis and therapy.
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
CA2452130A1 (en) 1992-03-05 1993-09-16 Francis J. Burrows Methods and compositions for targeting the vasculature of solid tumors
US5633149A (en) 1994-12-07 1997-05-27 Incyte Pharmaceuticals, Inc. Polynucleotide encoding novel chemokine expressed in inflamed adenoid
US6692920B1 (en) 1994-12-07 2004-02-17 Incyte Corporation Antibodies to a chemokine expressed in inflamed adenoid
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2222280A1 (en) 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-11 and human chemokine alpha-1
WO1998011226A2 (en) 1996-09-10 1998-03-19 Schering Corporation Mammalian chemokines, related reagents
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US20030207346A1 (en) 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
US6110695A (en) 1997-12-02 2000-08-29 The Regents Of The University Of California Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6723538B2 (en) 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2001072830A2 (de) 2000-03-31 2001-10-04 Ipf Pharmaceuticals Gmbh Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion
GB2361003A (en) 2000-04-07 2001-10-10 Astrazeneca Ab Novel compounds
US7052676B2 (en) 2000-09-26 2006-05-30 The Regents Of The University Of Michigan Methods for inhibition of HIV replication using a small molecule inhibitor
JP2004517078A (ja) 2000-12-01 2004-06-10 シェーリング　コーポレイション 哺乳動物遺伝子および関連試薬の使用
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US6818406B2 (en) 2001-03-23 2004-11-16 Mayo Foundation For Medical Education And Research Rheumatoid arthritis markers
US7442512B2 (en) 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
WO2003101485A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7964194B2 (en) 2002-11-15 2011-06-21 Morehouse School Of Medicine Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation
US7919083B2 (en) 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
US20070048301A1 (en) 2002-11-26 2007-03-01 Bodary-Winter Sarah C Compositions and methods for the treatment of immune related diseases
EP1613657A2 (en) 2003-03-28 2006-01-11 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
JP2007532656A (ja) 2004-04-12 2007-11-15 アメリカ合衆国 アデノウイルスベクターを用いて免疫応答を誘導するための方法
CA2501422C (en) 2004-04-29 2014-08-12 University Of Rochester Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease
JP4011100B2 (ja) 2004-07-09 2007-11-21 中外製薬株式会社 抗グリピカン３抗体
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
US20090041783A1 (en) 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
WO2007064911A1 (en) 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
GB0607774D0 (en) 2006-04-20 2006-05-31 Renovo Group Plc Medicaments
CA2646902C (en) 2006-04-21 2017-01-31 Centocor Inc. Cxcl13 antagonists and their use for the treatment of inflammatory diseases
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
JP2010523580A (ja) 2007-03-30 2010-07-15 セントコア・オーソ・バイオテツク・インコーポレーテツド Ｃｘｃｌ１３アンタゴニストおよび炎症性疾患の処置のためのそれらの使用
WO2010053547A2 (en) * 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Cxcr5 receptor compounds
MX353476B (es) 2010-09-02 2018-01-15 Vaccinex Inc Star Anticuerpos anti-cxcl13 y metodos para usarlos.
JP2015504060A (ja) 2011-12-28 2015-02-05 ノーベルメッド セラピューティクス インコーポレイテッド． アグリコシル化ヒト抗体および融合タンパク質、ならびにその使用
KR102176962B1 (ko) 2013-01-31 2020-11-10 백시넥스 인코포레이티드 면역글로불린 a 수준을 증가시키기 위한 방법
AU2013205589A1 (en) 2013-03-08 2014-09-25 Vaccinex, Inc. Anti-CXCL13 antibodies and associated epitope sequences

Also Published As

Publication number Publication date
WO2013130959A1 (en) 2013-09-06
AU2013225812A1 (en) 2014-09-25
EP2820045B1 (en) 2018-08-22
KR20140138830A (ko) 2014-12-04
US9890213B2 (en) 2018-02-13
CN104520323A (zh) 2015-04-15
JP2015509960A (ja) 2015-04-02
IN2014DN08199A (enExample) 2015-05-01
KR102090969B1 (ko) 2020-03-19
CN104520323B (zh) 2018-05-04
US20150125467A1 (en) 2015-05-07
JP6193275B2 (ja) 2017-09-06
EP2820045A1 (en) 2015-01-07
CA2865928A1 (en) 2013-09-06
AU2013225812B2 (en) 2017-11-30
CA2865928C (en) 2021-02-16

Similar Documents

Publication Publication Date Title
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
IN2015DN00450A (enExample)
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
PH12015502075B1 (en) Treatment of cataplexy
SG10201810615VA (en) Pd-1 / pd-l1 inhibitors for the treatment of cancer
EA201591687A1 (ru) Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
PH12015500169A1 (en) Prediction of treatment response to jak/stat inhibitor
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
GB201109238D0 (en) Antibodies
EA201891388A1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
MX2019013468A (es) Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab.
MX2015011386A (es) Metodo para tratar cancer pancreatico.
EA201591507A1 (ru) Лечение рассеянного склероза лахинимодом
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EA201690446A1 (ru) Лечение множественной миеломы
EA201690445A1 (ru) Лечение рака

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 01 MAR 2020 BY FISHER ADAMS KELLY CALLINANS

Effective date: 20170907

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2021 BY COMPUTER PACKAGES INC

Effective date: 20200218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2022 BY COMPUTER PACKAGES INC

Effective date: 20210306

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2023 BY COMPUTER PACKAGES INC

Effective date: 20220217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2024 BY COMPUTER PACKAGES INC

Effective date: 20230217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2025 BY COMPUTER PACKAGES INC

Effective date: 20240217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 01 MAR 2026 BY COMPUTER PACKAGES INC

Effective date: 20250217